ArticleInternational journal of clinical and experimental pathology2017
Leptin inhibits AMPKα2 down-regulation induced decrease in the osteocytic MLO-Y4 cell proliferation and the expression of osteogenic markers.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Metformin and bone metabolism: unraveling their direct and indirect effects.Therapeutic advances in endocrinology and metabolism · 2025Review
- The Function of Metformin in Aging-Related Musculoskeletal Disorders.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AMP-activated protein kinase (AMPK) is of biological and clinical importance for regulating cellular and systemic energy homeostasis. Although AMPKα1, one of the two AMPK's catalytic subunit α, expresses in the bone and stimulates bone nodule formation, the role of AMPKα2 in osteogenesis remains incompletely understood. The aim of this study was to determine the role of AMPKα2 in osteocytic MLO-Y4 cellproliferation and the expression of osteogenic markers. The current study silenced AMPKα2 in MLO-Y4 cells by transfection with pLKO.1-AMPKα2-shRNA vector and analyzed cell proliferation and the expression of osteogenic markers in MLO-Y4 cells with or without 100 μg/ml leptin treatment through CCK-8, Real-time PCR, Western blot and RNA-seq assay. We found that knockdown of AMPKα2 significantly decreased the mRNA level of AMPKα2 and the cell proliferation of MLO-Y4 cellsas well as the mRNA and protein levels of OPG, OCN, OPN, ALP and BMP6 and the protein expression of p-Smad5/Smad5. However, leptin treatment increased the MLO-Y4 cell proliferation and the expression of these osteogenic markers in MLO-Y4 cells with or without AMPKα2 silencing. Furthermore, RNA-seq assay showed 1019 transcriptors decreased in AMPKα2-silencing group and 995 transcriptors increased in leptin group compared with control group, respectively. 737 transcriptors decreased in AMPKα2-silencing group and 1282 transcriptors increased inleptin group compared with AMPKα2-silencing+leptin group, respectively. These findings suggest that AMPKα2 knockdown inhibited MLO-Y4 cell proliferation and osteogenic marker expressions, which implicates an important role of AMPKα2 in osteogenesis
Indexed as
Identifiers
31966708PMC6965451W2909706286What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.